Early diagnostics of prostate cancer based on a comprehensive analysis of risk factors
- Authors: Lazarev A.F.1, Petrova V.D.1, Lazarev S.A.1, Repkina T.V.1, Terekhova S.A.1, Obеremok P.A.2, Osipov I.S.3, Nikolaeva M.G.1, Ganov D.I.1
-
Affiliations:
- Altai State Medical University
- Consultative Diagnostic Center of the Altai Territory
- Medical Institute named after Berezin Sergey
- Issue: Vol 28, No 2 (2023)
- Pages: 109-118
- Section: Original Study Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/254436
- DOI: https://doi.org/10.17816/onco624300
- ID: 254436
Cite item
Abstract
BACKGROUND: There is a trend of increasing incidence and mortality from prostate cancer. Existing methods for early diagnosis and screening of prostate cancer did not demonstrate enough efficiency.
AIM: To improve the quality and efficiency of diagnostic measures for prostate cancer through a personalized approach to patients based on an analysis of a set of risk factors.
MATERIALS AND METHODS: The methodology was developed using the data from the population-based Cancer Registry of the Altai Territory, created at the Altai Regional Oncology Center in Barnaul, Russia. At the moment the Cancer Registry included information on 308 550 patients with malignant neoplasms, including 15 167 males with prostate cancer. On the basis of the method of prostate cancer risk assessment proposed by Lazarev AF an automated program for early diagnosis of prostate cancer has been developed. Testing of this technique included assessment of 532 patients (aged between 23 and 82).
RESULTS: 128 patients were determined to belong to the high risk pre-cancer group. A high-risk precancer registry was created, which included the patients having individual risk of developing prostate cancer either increased or high or absolute. Upon a set of in-depth examinations, 7 of 128 patients (9.3%) were diagnosed with prostate cancer, all at early stages (I or II). Thus, the incidence of prostate cancer among the patients from the high risk pre-cancer registry was significantly higher than the average observed during prophylactic examinations (0.01%).
CONCLUSION: The automated program for early diagnosis of prostate cancer could be implemented with the aim to assign in-depth examination in more targeted manner to patients at high risk of prostate cancer and to contribute to detection the cancer in the early stages.
Full Text
##article.viewOnOriginalSite##About the authors
Alexander F. Lazarev
Altai State Medical University
Email: lazarev@akzs.ru
ORCID iD: 0000-0003-1080-5294
Russian Federation, Barnaul
Valentina D. Petrova
Altai State Medical University
Email: valent_04@mail.ru
ORCID iD: 0000-0001-7169-9646
Russian Federation, Barnaul
Sergey A. Lazarev
Altai State Medical University
Email: serglazarev@bk.ru
ORCID iD: 0000-0001-7748-0784
Russian Federation, Barnaul
Tatiana V. Repkina
Altai State Medical University
Email: k-polter@asmu.ru
ORCID iD: 0000-0003-4583-313X
Barnaul
Svetlana A. Terekhova
Altai State Medical University
Author for correspondence.
Email: quip@list.ru
ORCID iD: 0009-0001-4594-4529
MD, Cand. Sci. (Medicine)
Russian Federation, BarnaulPavel A. Obеremok
Consultative Diagnostic Center of the Altai Territory
Email: pasha22ru@mail.ru
ORCID iD: 0009-0002-3250-6914
Russian Federation, Barnaul
Ilya S. Osipov
Medical Institute named after Berezin Sergey
Email: osipov_1989@bk.ru
ORCID iD: 0009-0008-4560-2933
Russian Federation, Barnaul
Maria G. Nikolaeva
Altai State Medical University
Email: k-ginek@asmu.ru
ORCID iD: 0000-0001-9459-5698
Russian Federation, Barnaul
Dmitriy I. Ganov
Altai State Medical University
Email: ganovdmit@yandex.ru
ORCID iD: 0000-0002-7118-1668
Russian Federation, Barnaul
References
- Surveillance, Epidemiology, and End Results Program. Prostate cancer. USA: National Cancer Institute. [cited 01 Jan 2023]. Available from: http://www.seer.cancer.gov
- Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
- Kaprin AD, Starinskii VV, Shakhzadova AO, editors. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Moscow: P.A. Herzen MNIOI — branch of FGBU NMC Radiology of the Ministry of Health of Russia; 2022. (In Russ).
- Kaprin AD, Starinskii VV, Shakhzadova AO, editors. State of oncological care for the Russian population in 2022. Moscow: P.A. Herzen MNIOI — branch of FGBU NMC Radiology of the Ministry of Health of Russia; 2023. (In Russ).
- Sergeeva NS, Skachkova TE, Marshutina NV, Alekseev BYa, Kaprin AD. Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. Onkologiya. Zhurnal im. P.A. Gertsena. 2018;7(1):55–67. EDN: YRTOMF doi: 10.17116/onkolog20187155-67
- Pushkar’ DYu, Rasner PI. Differential diagnosis of cancer and benign prostatic hyperplasia. Russian Medical Journal. 2014;22(17):1298–1303. (In Russ). EDN: SKBOXD
- Prostate cancer. Clinical guidelines. ID 12. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2021. Available from: https://cr.minzdrav.gov.ru/recomend/12_3
- Patent RUS № 2692987/ 28.06.2019. Lazarev AF. Method for determining the risk of prostate cancer. (In Russ).
- Certificate of state registration of the computer program № 2019663514/ 17.10.2019. Lazarev AF, Pokornyak VP, Marchkov VA, Lazarev SA, Petrova VD. Automated program for early diagnosis of prostate cancer (PC). (In Russ).
- Certificate of state registration of the computer program №2008611703/ 31.03.2008. Lazarev AF. Territorial Cancer Registry (In Russ).